Citadel Advisors’s Eterna Therapeutics ERNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $100K | Buy |
15,104
+13,781
| +1,042% | +$97.9K | ﹤0.01% | 12700 |
|
|
2026
Q1 | $6.58K | Buy |
+1,323
| New | +$21.1K | ﹤0.01% | 12796 |
|
|
2025
Q2 | – | Sell |
-175
| Closed | -$11.7K | – | 13199 |
|
|
2025
Q1 | $11.7K | Buy |
+175
| New | +$21.6K | ﹤0.01% | 13478 |
|
|
2024
Q2 | – | Sell |
-27
| Closed | -$24.1K | – | 14539 |
|
|
2024
Q1 | $24.1K | Buy |
+27
| New | +$18.6K | ﹤0.01% | 12873 |
|
|
2022
Q4 | – | Sell |
-7
| Closed | -$13K | – | 14986 |
|
|
2022
Q3 | $13K | Sell |
7
-21
| -75% | -$72.4K | ﹤0.01% | 12197 |
|
|
2022
Q2 | $107K | Buy |
28
+5
| +22% | +$35.9K | ﹤0.01% | 11348 |
|
|
2022
Q1 | $349K | Buy |
23
+7
| +44% | +$133K | ﹤0.01% | 10241 |
|
|
2021
Q4 | $490K | Buy |
16
+14
| +700% | +$761K | ﹤0.01% | 9745 |
|
|
2021
Q3 | $142K | Buy |
+2
| New | +$173K | ﹤0.01% | 12441 |
|
|
2021
Q2 | – | Sell |
-3
| Closed | -$432K | – | 13846 |
|
|
2021
Q1 | $85K | Buy |
3
+2
| +200% | +$108K | ﹤0.01% | 12597 |
|
|
2020
Q4 | $32K | Buy |
+1
| New | +$30.4K | ﹤0.01% | 10698 |
|
|
2020
Q1 | – | Sell |
-1
| Closed | -$38K | – | 9723 |
|
|
2019
Q4 | $38K | Buy |
+1
| New | +$42.6K | ﹤0.01% | 8818 |
|
|
2019
Q3 | – | Sell |
-1
| Closed | -$59K | – | 9303 |
|
|
2019
Q2 | $59K | Buy |
+1
| New | +$52.4K | ﹤0.01% | 8677 |
|
|
2018
Q4 | – | Sell |
-2
| Closed | -$110K | – | 9268 |
|
|
2018
Q3 | $110K | Buy |
+2
| New | +$144K | ﹤0.01% | 8536 |
|
|
2016
Q1 | – | Hold |
0
| – | -$2K | – | 7078 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 8574 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 8092 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 8538 |
|
|
2015
Q1 | – | Hold |
0
| – | -$18K | – | 8603 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 7890 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 7750 |
|
|
2013
Q3 | – | Hold |
0
| – | -$12K | – | 6767 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 6191 |
|
Other funds holding ERNA
DIG
Citadel Advisors's ERNA Position: Q2 2026 in Review
Citadel Advisors increased its Eterna Therapeutics (ERNA) stake by 1,042% in Q2 2026, buying an estimated $97.9K and bringing the position to 15,104 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #12700.
Citadel Advisors first reported a position in ERNA in Q3 2018 and has held it in 14 quarters since. The position peaked at $490K in Q4 2021. 9 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.
- Citadel Advisors held 15,104 shares of Eterna Therapeutics worth $100K as of Q2 2026.
- Citadel Advisors bought 13,781 Eterna Therapeutics shares in Q2 2026, an estimated $97.9K.
- Eterna Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12700 holding.
- Citadel Advisors first reported a position in Eterna Therapeutics in Q3 2018 and has held it in 14 quarters since.
- Citadel Advisors's Eterna Therapeutics position peaked at $490K in Q4 2021.
- 9 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.